An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.
Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis
Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin
2 Clarke Drive Cranbury, NJ 08512